| La Bonne Vie Family Healthcare & Aesthetics, Llc | |
|
238 E Main St Ville Platte LA 70586-4606 | |
| (337) 363-5591 | |
| (337) 363-6565 |
| Full Name | La Bonne Vie Family Healthcare & Aesthetics, Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 238 E Main St, Ville Platte, Louisiana |
| Authorized Official Name and Position | Brittany F. Miller (OWNER) |
| Authorized Official Contact | 3373635591 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| La Bonne Vie Family Healthcare & Aesthetics, Llc 238 E Main St Ville Platte LA 70586-4606 Ph: (337) 363-5591 | La Bonne Vie Family Healthcare & Aesthetics, Llc 238 E Main St Ville Platte LA 70586-4606 Ph: (337) 363-5591 |
| NPI Number | 1235596024 |
|---|---|
| Provider Enumeration Date | 01/25/2016 |
| Last Update Date | 04/29/2024 |
| Medicare PECOS PAC ID | 5890079602 |
|---|---|
| Medicare Enrollment ID | O20170222002318 |
News Archive
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
The location of an ectopic pregnancy can be determined using a simple, noninvasive physical examination technique used by osteopathic physicians, researchers say.
Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
A middle-aged woman makes plans over the telephone to get together with a friend, even though she cannot talk after suffering a stroke.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235596024 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | AP08602 (Louisiana) | Secondary |
| 261QR1300X | Clinic/center - Rural Health | (* (Not Available)) | Primary |
| Provider Name | Brittany F Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255798344 PECOS PAC ID: 6709160518 Enrollment ID: I20170223001498 |
News Archive
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
The location of an ectopic pregnancy can be determined using a simple, noninvasive physical examination technique used by osteopathic physicians, researchers say.
Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
A middle-aged woman makes plans over the telephone to get together with a friend, even though she cannot talk after suffering a stroke.
› Verified 9 days ago
| Provider Name | Sarah Matte Lemoine |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295417657 PECOS PAC ID: 1254789712 Enrollment ID: I20231122001977 |
News Archive
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
The location of an ectopic pregnancy can be determined using a simple, noninvasive physical examination technique used by osteopathic physicians, researchers say.
Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
A middle-aged woman makes plans over the telephone to get together with a friend, even though she cannot talk after suffering a stroke.
› Verified 9 days ago
News Archive
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
The location of an ectopic pregnancy can be determined using a simple, noninvasive physical examination technique used by osteopathic physicians, researchers say.
Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
A middle-aged woman makes plans over the telephone to get together with a friend, even though she cannot talk after suffering a stroke.
› Verified 9 days ago
Evangeline Family Medicine Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 505 E Lincoln Rd, Ville Platte, LA 70586 Phone: 337-942-3390 Fax: 337-942-8644 | |
Aswell Rural Health Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 503 Jack Miller Rd, Suite A, Ville Platte, LA 70586 Phone: 337-363-7474 | |
Heinen Medical Vp Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1535 W Main St Ste 6, Ville Platte, LA 70586 Phone: 337-363-5521 Fax: 337-363-9134 | |
Henry J. Dupre, M.d. Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1008 W Main St, Ville Platte, LA 70586 Phone: 337-363-5531 Fax: 337-363-5250 | |
Charles J Aswell Iii Md A Prof Medical Corp Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 503 Jack Miller Road, Ste A, Ville Platte, LA 70586 Phone: 337-363-7474 Fax: 337-363-1197 | |
Just Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 Court St Ste 200, Ville Platte, LA 70586 Phone: 833-784-2669 Fax: 844-784-2329 | |
Thomas G. Fontenot, Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 East Lincoln Road, Ville Platte, LA 70586 Phone: 337-363-7744 |